Long-term safety of topical pimecrolimus and topical tacrolimus in atopic blepharoconjunctivitis.
Ville
V
Kiiski
Anita
A
Remitz
Sakari
S
Reitamo
Johanna
J
Mandelin
Osmo
O
Kari
D000287:Administration, Topical; D000328:Adult; D001762:Blepharitis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology*; D015331:Cohort Studies; D003233:Conjunctivitis, Allergic / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D016208:Databases, Factual; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005387:Finland; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D061214:Patient Safety; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016559:Tacrolimus / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
C117268:pimecrolimus; D016559:Tacrolimus